report- Acute-Myelocytic-Leukemia-AML-Acute-Myeloblastic-L | Page 6

Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting 56 Dec 05, 2016: BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016 57 Dec 05, 2016: Preclinical Data on IMGN632, a Novel CD123-Targeting ADC, Presented at ASH Annual Meeting 58 Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 58 Dec 05, 2016: Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARa Agonist for Genomically Defined Subsets of AML and MDS Patients 59 Dec 05, 2016: Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting 60 Dec 05, 2016: Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting 60 Dec 05, 2016: Cornerstone Pharmaceuticals Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin Lymphoma (T-cell NHL) at ASH 2016 61 Dec 05, 2016: ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting 62 Dec 04, 2016: Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting 63 Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome 64 Dec 03, 2016: Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting 64 Dec 03, 2016: Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies